Memorial Sloan Kettering Cancer Center

FDA approves Roche’s Itovebi (inavolisib) in combination with palbociclib and fulvestrant for HR-positive, HER2-negative, PIK3CA-mutated breast cancer, based on INAVO120 study results showing a 57% reduction in disease worsening or death risk.

FDA approves Genentech's Itovebi (inavolisib) for HR+/HER2- breast cancer with PIK3CA mutation, in combo with Ibrance and fulvestrant. FoundationOneLiquid CDx is approved as a companion diagnostic. Itovebi aims to reduce toxicity of other PI3K inhibitors, with a 28-day cycle costing $22,867. Phase 3 INAVO120 data showed Itovebi regimen doubled progression-free survival vs. Ibrance and fulvestrant alone, reducing risk of disease worsening or death by 57%.

FDA approves Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant for HR-positive, HER2-negative breast cancer with PIK3CA mutation, based on INAVO120 study showing doubled progression-free survival.

FDA approves Itovebi (inavolisib) in combination with palbociclib and fulvestrant for HR-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer, based on INAVO120 study results showing significant progression-free survival improvement.

FDA approves Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant for HR-positive, HER2-negative, PIK3CA-mutated breast cancer, based on INAVO120 study results showing doubled progression-free survival.

FDA approves Itovebi (inavolisib) for HR-positive, HER2-negative breast cancer with PIK3CA mutation, in combination with palbociclib and fulvestrant.

FDA approves Itovebi (inavolisib) for HR-positive, HER2-negative breast cancer with PIK3CA mutation, in combination with palbociclib and fulvestrant, based on INAVO120 study results showing significant progression-free survival improvement.

FDA approves inavolisib (Itovebi) in combination with palbociclib and fulvestrant for locally advanced, PIK3CA-mutated, HR-positive/HER2-negative breast cancer. INAVO120 trial showed inavolisib more than doubled median progression-free survival (PFS) to 15 months from 7.3 months. Common adverse events include neutrophil, hemoglobin, and platelet decreases, and increases in fasting glucose and creatinine.

Durvalumab showed similar radiation pneumonitis incidences to placebo in LS-SCLC patients, with manageable safety profile, according to ADRIATIC trial results presented at 2024 ASTRO Annual Meeting.

FDA approves Genentech's Itovebi for HR-positive, HER2-negative breast cancer with PIK3CA mutation, based on INAVO120 study showing doubled progression-free survival.